CN1142155C - Antineoplastic medicine and its preparing process - Google Patents
Antineoplastic medicine and its preparing process Download PDFInfo
- Publication number
- CN1142155C CN1142155C CNB001172255A CN00117225A CN1142155C CN 1142155 C CN1142155 C CN 1142155C CN B001172255 A CNB001172255 A CN B001172255A CN 00117225 A CN00117225 A CN 00117225A CN 1142155 C CN1142155 C CN 1142155C
- Authority
- CN
- China
- Prior art keywords
- ampelopsis
- ampelopsin
- water
- extraction
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to an antitumor medicine and a preparation method thereof. The medicine is ampelopsin. Dried complete stools or roots or leaves of ampelopsis cantoniensis, ampelopsis, leaflet ampelopsis, dentigerous ampelopsis and smooth leaved ampelopsis which are vitaceae ampelopsis plants are taken, and the alcohol back flow and the extraction are carried out so as to recover alcohol. Proper quantities of water is added, petroleum ether and chloroform are used for extraction, and a water layer is in reduced pressure distillation so as to extract solid. The filtration is carried out, the obtained solid dissolves in water, and active carbon is added for boiling. The filtration and the standing operation are carried out under the heating condition so as to extract crystals, namely ampelopsin. The antitumor medicine has the advantages of definite curative effect, high curative effect and little toxic side effect, and has a wide antitumour spectrum. The extraction rate of the preparation method is high.
Description
The present invention relates to the application of a kind of compound ampelopsin in the preparation antitumor drug.
Vitaceae ampelopsis ampelopsis cantoniensis (Ampelopsis cantoniensis Planch) mainly abounds with in China south China one band, (" Chinese medicine voluminous dictionary " claims that " no acupuncture root " or complete stool are traditional medications among the people to its root, be widely used in eliminating inflammation and expelling toxin, control infectious diseases such as tetter, furuncle and osteomyelitis, acute lymphoblastic inflammation, evident in efficacy.The dry products of this plant " white tea " (claiming " vine tea ", " rattan mother-in-law tea " again) always be among the people do refreshing and detoxicating for the tea-drinking product.Domesticly began the ampelopsin in the ampelopsis cantoniensis is carried out structure discriminating, assay and Antioxidation Effects in 1989.For congener, except going into the officinal radix ampelopsis, also have Stem or leaf of Amur Ampelopsis, leaflet Stem or leaf of Amur Ampelopsis, Ampelopsis grossedentata, Ampelopsis etc., they all have effects such as eliminating inflammation and expelling toxin, promoting blood circulation to remove blood stasis, swelling and pain relieving.
At present as yet not relevant for the report of the tumor inhibition effect of ampelopsin.The extracting method of bibliographical information ampelopsin be medicinal material through pure heat extract behind the total flavones, take (1) to go up polyamide column chromatography and separate, with a large amount of methanol aqueous solution wash-outs; (2) go up silica gel column chromatography and separate, with a large amount of binary or ternary organic solvent wash-out.Above-mentioned two kinds of methods are all used the relatively large bigger toxic organic solvent that has, and long flow path and yield are low, are not suitable for industrialized production.
Purpose of the present invention is exactly for a kind of determined curative effect, curative effect height, toxic side effect is little, extraction efficiency is high antitumor drug and production method thereof are provided.
The present invention realizes like this.
Get exsiccant complete stool or the root or the leaf of Vitaceae ampelopsis ampelopsis cantoniensis, Stem or leaf of Amur Ampelopsis, leaflet Stem or leaf of Amur Ampelopsis, Ampelopsis grossedentata, Ampelopsis, bulk drug earlier with 30～100% alcohol-pickled spending the night, filters after crushed.The dregs of a decoction extract 1～3 time with reflow of alcohol again.Filter.Merging filtrate.Recovered alcohol adds suitable quantity of water to there being solid to separate out, and makes the solid dissolving.Use petroleum ether extraction 2 times earlier, use chloroform extraction again 3 times, divide and remove organic solvent.Water layer liquid underpressure distillation to solid is separated out, and through standing over night, separates out a large amount of precipitations, filters.The gained solid adds the entry heating for dissolving again, adds Powdered Activated Carbon, after boiling, and filtered while hot.Filtrate go up for another example method through leave standstill, crystallization, water dissolution, the activated carbon removal of impurity and recrystallization, totally 1～3 time.Collect crystallization at last, after 40 ℃ of dryings of vacuum, get white, needle-shaped crystals.Get above-mentioned crystallization, it is as follows to measure its physico-chemical property: white, needle-shaped crystals, mp246～247 ℃.Be soluble in hot water, hot ethanol, be dissolved in methyl alcohol, ethanol, acetone, be slightly soluble in water, ethyl acetate, be insoluble in chloroform, sherwood oil.
Carrying out structure identifies:
[ultimate analysis] C
15H
12O
8Experimental value (%): C56.O4, H3.79; Calculated value (%): C56.25, H3.78
[FAB-MS]m/z：321(M
++1)，315，304，292(M
+-CO)，291(M
+-CHO)，259，241，223，186，167，153，149，139，124
[UV]λ
max MeOH，nm(logε)：290.5(4.27)，226.5(4.41)
[IR]]y
max KBr，cm
-1：3200～3600(-OH)，1717，1640(＞＝O)，1600，1548，1509，1472，1166，1084，1026，840
[
1H-NMR](DMSO-d
6)δ(ppm)：11.89(1H，s，C
3-OH)，10.85(1H，s，C
5-OH)，5.85(2H，d，J＝15.6Hz，C
6，8-H)，5.75(1H，s，C
7-OH)，4.41(1H，d，J＝10.8Hz，C
3-H)，4.90(1H，d，J＝10.8Hz，C
2-H)，6.39(2H，s，C
2’，6’-H)，8.23(1H，s，C
4’-OH)，8.93(2H，s，C
3’5’-OH)
[
13C-NMR](DMS0-d
6)δ(ppm)：83.3，71.7，197.8，166.9，163.4，162.6，145.8，133.5，127.2，107.3，106.8，100.6，96.1，95.1，94.9
By analysis, its structural formula is
3,5,7,3 ', 4 ', 5 '-hexahydroxy-2,3.dihydroflavonol, ampelopsin (dihydromyricetin)
Chemical name: 3,5,7,3 ', 4 ', 5 ' ,-hexahydroxy--2, the 3-flavanone,
Have another name called: ampelopsin, dihydromyricetin flavine, Ampelopstin
Ampelopsin is injected through mouse peritoneal, and LD50 is that (95% can be limited to 866～1236mg/kg) to 1034mg/kg, shows that the ampelopsin application is safer.The LD50 of antitumour drug dacarbazine is 859mg/kg by comparison.
(1) ampelopsin to the mouse transplantability melanomatous inhibition test 1. experiment materials [medicine and reagent]: injection dacarbazine (DTIC), tetrazolium bromide (MTT), iodine third pyridine (PI); RMPI-medium 1640:HEPES.[animal]: C57BL/6 mouse, male and female dual-purpose, body weight (20 ± 2) g.[cell strain]: murine melanoma B16 cell.2.C57BL/6 mouse transplantability melanoma suppresses experiment 2.1 animal lotus knurls
Collect logarithmic phase murine melanoma B16 cell, use the water for injection washed twice, the centrifugal 5min of 1000rpm abandons or adopts supernatant liquor, and the B16 cell is resuspended in the physiological saline, and being diluted to concentration is 1 * 10
7The single cell suspension of individual/ml.It is subcutaneous to be inoculated in C57BL/6 mouse both sides inguinal region under the aseptic condition, and inoculum size is that every 0.1ml cell suspension (is equivalent to 1 * 10
6Individual/only) 2.2 dosage regimens
The C57BL/6 mouse, behind inoculation B16 cell first day, by the grouping of body weight completely random.1/10～1/5LD in ampelopsin
50Between establish three dosage groups, be respectively 0.280mmol/kg, 0.420mmol/kg, 0.560mmol/kg; Other establishes physiological saline negative control group, solvent control group, and 0.330mmol/kg dacarbazine positive controls, 10 of every group of mouse.From inoculating back the 5th day, continuous intraperitoneal injection 9 days (once a day).2.3 soup preparation
Ampelopsin 0.280,0.420,0.560mmol/kg dosage group are solvent with 30% dimethyl sulfoxide (DMSO) all, and 0.330mmol/kg dacarbazine positive controls is solvent with physiological saline.(soup is preparation temporarily all, with 0.22 μ m filtering with microporous membrane degerming) 2.4 melanoma growth inhibition ratios (GI)
Melanoma effect in the body of ampelopsin is estimated with the melanomatous growth inhibition ratio of transplantability.Behind the tumor-bearing mice successive administration 9 days, put to death behind the drug withdrawal 24h.Peel off the melanoma lump weigh with each treatment group knurl heavily be index and control group knurl anharmonic ratio, estimate the effect of ampelopsin melanoma in vivo, ampelopsin the results are shown in Table 1 to the melanomatous growth-inhibiting of mouse transplantability.It is different that each organizes the knurl method of double differences, uses SPSS PC/windows 9.0 statistical softwares and make one-way analysis of variance.
Table 1 ampelopsin is to the melanomatous growth-inhibiting result of mouse transplantability
Heavy (g) inhibiting rate % of group N (only) knurl t-checks 30% dimethylsulfoxide solvent control group, 10 2.1700 ± 0.7394 // ampelopsin 0.280mmol/kg dosage group, 10 1.7150 ± 0.2887 25.76 P＜0.05 ampelopsin 0.420mmol/kg dosage group, 10 1.5700 ± 0.5599 32.03 P＜0.05 ampelopsin 0.560mmol/kg dosage group, 10 1.0500 ± 0.2953 54.55 P＜0.05DTIC positive controls 0.330mmol/kg 10 0.9430 ± 0.5031 59.18 P＜0.05 physiological saline control group, 10 2.3100 ± 0.4909 // 2.5 ampelopsins to the melanomatous growth inhibition result of mouse transplantability
Ampelopsin 0.280mmol/kg, 0.420mmol/kg, 0.560mmol/kg dosage group mouse successive administration be after 9 days, and murine melanoma knurl weight average has significantly and reduces (P＜0.05), and inhibiting rate is respectively 25.76%, 32.03%, 54.55%.3 dosage groups all can effectively suppress the growth of murine melanoma, and ampelopsin 0.560mmol/kg dosage group and 0.330mmol/kg dacarbazine positive controls therapeutic equivalence.3. flow cytometer is surveyed the influence of pastille serum to B16 cell cycle and propagation
Concentration is 5.25 * 10
4The B16 cell of individual/ml is seeded in the 25ml culturing bottle by the 4ml/ bottle.At 5%CO
2, cultivate 24h under 37 ℃ of (saturated humidity) conditions after, add the mouse 10min time point pastille serum 1ml (the serum add-on that is equivalent to 20% volume) of ampelopsin 0.420mmol/kg and 0.560mmol/kg dosage group.At 5%CO
2, continue to cultivate 72h under 37 ℃ of (saturated humidity) conditions, collecting cell with the RMPI-1640 nutrient solution of serum-free with cell washing after, resuspended be single cell suspension, adds-20 ℃ of precooled ethanol (make contain alcohol measure to 70%) and fixes, to be measured.The PI 30min that dyes filters flow cytometer detection level and cell cycle distribution, software processing result with 350 eye mesh screens.Calculate cell fission proliferation index (PI)=(S+G according to formula
2M)/(G
1+ S+G
2M) * 100%.Ampelopsin pastille serum influenced as table 2. cycle of B16 cell
Table 2. ampelopsin pastille serum is to the cycle influence of B16 cell
G1 (%) S (%) G2M (%) PI (%) blank 61.8 26.1 12.8 38.60.420mmol/kg dosage group pastille serum 68.6 14.3 17.1 31.40.560mmol/kg dosage group pastille serum 69.6 11.4 19 30.4
Under the effect of 2 kinds of dosage group ampelopsin pastille serum, murine melanoma B16 cell all shows as G
1Phase and G
2The M phase cell content not dosing negative control group cell that compares has in various degree rising; The S phase cell content not dosing negative control group cell that compares then has in various degree decline; The cell fission proliferation index all reduces; It is synthetic to show that ampelopsin might suppress the DNA of cell.(2) ampelopsin is to the inhibition effect of people's tumour cell
1. ampelopsin is 2.7 * 10
-4Under the concentration of mol/L, human promyelocytic leukemia HL60 cell inhibiting rate is reached 94.1%, IC
50Be 3.4 * 10
-5Mol/L; To K562 cell inhibiting rate is 88.9%, its IC
50Be 5.0 * 10
-5Mol/L;
2. ampelopsin is to the IC of human nasopharyngeal carcinoma HK-1 cell strain
50Be 1.4 * 10
-4Mol/L;
3. ampelopsin is to the IC of human hepatocellular carcinoma BEL-7402 cell's strain
50Be 1.1 * 10
-4Mol/L.
The result represents that ampelopsin all has good inhibitory effect to melanoma and several people's tumour cell.Prompting is a kind of broad-spectrum anti-cancer drug.
Ampelopsin is prepared on the pharmaceutics said any formulation comprises oral dosage form such as tablet, electuary, capsule, oral liquid etc., also can be prepared into injection type, as powder ampoule agent for injection, injection liquid etc.; Also can make targeting preparation, as liposome etc.The auxiliary material of the preparation that adopts is a pharmaceutics auxiliary material commonly used, and production method is made required formulation routinely.Can also make compound preparation with other antitumor drug compound.
Contain weight ratio in the pharmaceutical dosage form of the present invention and be 0.01～99.5% ampelopsin.
Amount of drug of the present invention can change according to route of administration, patient's age, body weight, tumor type.Its dosage can be 0.5～1g, can subcutaneous or intramuscular injection, or intravenous injection or instillation, also can oral medication.
The invention will be further described below in conjunction with drawings and Examples.
Embodiment 1 extracts ampelopsin from ampelopsis cantoniensis.
Get dry complete stool or the tender leaf or the root of Vitaceae ampelopsis ampelopsis cantoniensis, bulk drug with medicinal alcohol (95%) soaked overnight of 2 times of volumes, filters earlier after crushed.The dregs of a decoction extract 3 times with 95% reflow of alcohol of equal volume amounts again.Filter.Merging filtrate.Recovered alcohol adds suitable quantity of water to there being solid to separate out, and makes the solid dissolving.Earlier with isopyknic 60～90 ° of petroleum ether extractions 2 times, use isopyknic chloroform extraction 3 times again, branch removes chloroform layer.Water layer liquid underpressure distillation to solid is separated out, and through standing over night, separates out a large amount of precipitations, filters.The gained solid adds 3 times of weight water heating for dissolving again, adds the Powdered Activated Carbon of solution total amount 1%～2%, boils 10 minutes, takes advantage of heat filtering.Filtrate go up for another example method through leave standstill, crystallization, water dissolution, the activated carbon removal of impurity and recrystallization, totally 3 times.Collect crystallization at last, after 40 ℃ of dryings of vacuum, get white, needle-shaped crystals.
Get ampelopsin 100 gram of said extracted, be dissolved in an amount of 2% the tween-80, add an amount of N.F,USP MANNITOL again,, make subcutaneous or the intramuscular injection powder ampoule agent for injection through freeze-drying.
In the present embodiment 1, the yield of ampelopsin is 10.2%, and purity is more than 98%.
Embodiment 2, extract ampelopsin from Stem or leaf of Amur Ampelopsis, and make tablet.
Get exsiccant complete stool or tender leaf or the root of Stem or leaf of Amur Ampelopsis, bulk drug with medicinal alcohol (50%) soaked overnight of 3 times of volumes, filters earlier after crushed.The dregs of a decoction extract 3 times with 50% reflow of alcohol of half volume again.Filter.Merging filtrate.Recovered alcohol adds suitable quantity of water to there being solid to separate out, and makes the solid dissolving.Earlier with isopyknic 60～90 ° of petroleum ether extractions 2 times, use isopyknic chloroform extraction 3 times again, branch removes organic solvent.Water layer liquid underpressure distillation to solid is separated out, and through standing over night, separates out a large amount of precipitations, filters.Weight water heating for dissolving such as the gained solid adds again, the Powdered Activated Carbon of adding solution total amount 4%～5% boiled filtered while hot 10 minutes.Filtrate go up for another example method through leave standstill, crystallization, water dissolution, the activated carbon removal of impurity and recrystallization, totally 4 times.Collect crystallization at last, after 40 ℃ of dryings of vacuum, get white, needle-shaped crystals.
Get the ampelopsin of said extracted, add starch and granulate, add talcum powder, Magnesium Stearate compressing tablet, make the ampelopsin tablet.
Embodiment 3, with the Stem or leaf of Amur Ampelopsis among the embodiment 2, change the leaflet Stem or leaf of Amur Ampelopsis into, and its extracting method is with embodiment 2.Get the ampelopsin of said extracted, the propylene glycol dissolving with containing an amount of ethanol 20% adds N.F,USP MANNITOL again, makes ampelopsin injection for intravenous powder injection.
Embodiment 4, change the ampelopsis cantoniensis among the embodiment 1 into Ampelopsis grossedentata, and its extracting method is made capsule according to a conventional method with embodiment 1.
Embodiment 5, change the ampelopsis cantoniensis among the embodiment 1 into Ampelopsis, and the ethanol concn of refluxing extraction is changed to 30%, and its extraction process is made oral liquid according to a conventional method with embodiment 1.
Various embodiments of the present invention have identical curative effect.The invention is not restricted to the foregoing description.
Claims (2)
1, the application of ampelopsin in the preparation anti-leukemia medicine:
Chemical name: 3,5.7,3 ', 4 ', 5 '-hexahydroxy--2,3-flavanone
2, the application of ampelopsin in the anti-medicine for nasopharyngeal of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001172255A CN1142155C (en) | 2000-07-05 | 2000-07-05 | Antineoplastic medicine and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001172255A CN1142155C (en) | 2000-07-05 | 2000-07-05 | Antineoplastic medicine and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1304934A CN1304934A (en) | 2001-07-25 |
| CN1142155C true CN1142155C (en) | 2004-03-17 |
Family
ID=4586608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001172255A Expired - Fee Related CN1142155C (en) | 2000-07-05 | 2000-07-05 | Antineoplastic medicine and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1142155C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117922A1 (en) * | 2004-06-04 | 2005-12-15 | Bright Future Pharmaceutical Laboratories Limited | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305868C (en) * | 2004-06-25 | 2007-03-21 | 广东省农业科学院蚕业与农产品加工研究所 | Extraction of dihydromyricetin from microwave and composition thereof |
| CN101045721B (en) * | 2006-03-31 | 2011-01-12 | 兰州大学 | Preparation of porcelain vine element unsaturated sodium salt and its application |
| CN102038190A (en) * | 2009-10-23 | 2011-05-04 | 任启生 | Application of ampelopsin to preparation of anti-mutagenic health-care foods and medicaments |
| CN102048160A (en) * | 2009-10-28 | 2011-05-11 | 任启生 | Use of ampelopsin in preparation of healthcare food and medicaments for protecting vascular endothelial cells |
| CN103622948A (en) * | 2013-09-25 | 2014-03-12 | 广东医学院附属医院 | Application of dihydromyricetin in preparation of medicine for preventing leukemia cell cycle arrest |
| CN103933026A (en) * | 2013-09-25 | 2014-07-23 | 广东医学院附属医院 | Application of dihydromyricetin in drug for promoting leukemia cells to continue to differentiate |
| CN103772338A (en) * | 2014-01-10 | 2014-05-07 | 吉首大学 | Vacuum pulse type method of preparing dihydromyricetin |
| CN105061533B (en) * | 2015-09-18 | 2018-02-09 | 福州大学 | Hexa methoxy flavanone rhamnopyranosyl rhamnoside and its application |
-
2000
- 2000-07-05 CN CNB001172255A patent/CN1142155C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117922A1 (en) * | 2004-06-04 | 2005-12-15 | Bright Future Pharmaceutical Laboratories Limited | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1304934A (en) | 2001-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1142155C (en) | Antineoplastic medicine and its preparing process | |
| CN101019893B (en) | Process of enriching effective antitumor part of periplaneta americana with polyamide | |
| CN101057872A (en) | Anti tumor active part of American cockroach prepared with reverse phase material and medical application | |
| CN108210547B (en) | Preparation method of phyllanthus emblica leaf extract, preparation and anti-artemisia application thereof | |
| CN102293866A (en) | Camellia chrysantha capsule assisting hypoglycemic effect and preparation method thereof | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN105963304A (en) | Medicinal composition containing melbine as well as ursolic acid and ursolic acid derivatives and application to preparation of anti-tumor medicines thereof | |
| CN102100833B (en) | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof | |
| CN100502898C (en) | Honeysuckle extract, preparation and use thereof | |
| CN1067258C (en) | Medicinal preparation with extractive from yangtao root and preparing process thereof | |
| CN103012560B (en) | Preparation method of cyclic peptide compound from cortex lycii radicis | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| CN102093380B (en) | Cyclic icaritin aglycon as well as preparation method and application of cyclic icaritin aglycon | |
| CN111000919A (en) | Application of ethanol extract of evodia lepta in preparation of medicine for treating sepsis | |
| CN100532395C (en) | Alpha-glucosan originated from Grifola frondosa sporophore and its preparation process and use | |
| CN1686198A (en) | Oral administration medicinal preparation prepared using notoginseng, salvia root and erigeron breviscapus extracts | |
| CN100525759C (en) | Ready-made medicine of traditional chinese medicine for treating ischemic cranial vascular disease | |
| CN108635426A (en) | A kind of Colestid traditional Chinese drug inspissation water-bindered pill and preparation process | |
| CN103393738B (en) | Traditional Chinese medicine composition for preventing influenza A viruses H1N1 | |
| CN1219539C (en) | Immune regulator prepared from waste material in preparing Mailuoning injection process and its use in producing medicine | |
| CN1823811A (en) | Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes | |
| CN1457797A (en) | Composition with anti-virus function and its preparing process | |
| CN1301113C (en) | Method for making preparation of rhodiola root | |
| CN1935183A (en) | Chinese medicine compound preparation and its preparing method | |
| CN112843177A (en) | Application of anoectochilus formosanus extract in preparation of medicine or health-care product for treating or relieving pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |